JP2020502151A5 - - Google Patents

Info

Publication number

JP2020502151A5

JP2020502151A5 JP2019532043A JP2019532043A JP2020502151A5 JP 2020502151 A5 JP2020502151 A5 JP 2020502151A5 JP 2019532043 A JP2019532043 A JP 2019532043A JP 2019532043 A JP2019532043 A JP 2019532043A JP 2020502151 A5 JP2020502151 A5 JP 2020502151A5

Authority

JP

Japan

Prior art keywords

plasminogen

pharmaceutical composition

drugs

use according

blood glucose

Prior art date

2017-06-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000013566 Plasminogen Human genes 0.000 claims 16
• 108010051456 Plasminogen Proteins 0.000 claims 16
• 239000008194 pharmaceutical composition Substances 0.000 claims 15
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 8
• 206010012601 diabetes mellitus Diseases 0.000 claims 8
• 239000008103 glucose Substances 0.000 claims 8
• 210000004369 blood Anatomy 0.000 claims 6
• 239000008280 blood Substances 0.000 claims 6
• 229940079593 drug Drugs 0.000 claims 5
• 239000003814 drug Substances 0.000 claims 5
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
• 210000002966 serum Anatomy 0.000 claims 4
• 239000003146 anticoagulant agent Substances 0.000 claims 3
• 230000000694 effects Effects 0.000 claims 3
• 230000003914 insulin secretion Effects 0.000 claims 3
• 210000004153 islets of langerhan Anatomy 0.000 claims 3
• 230000028327 secretion Effects 0.000 claims 3
• 102000051325 Glucagon Human genes 0.000 claims 2
• 108060003199 Glucagon Proteins 0.000 claims 2
• 102000004877 Insulin Human genes 0.000 claims 2
• 108090001061 Insulin Proteins 0.000 claims 2
• 229940127219 anticoagulant drug Drugs 0.000 claims 2
• 239000003472 antidiabetic agent Substances 0.000 claims 2
• 239000002220 antihypertensive agent Substances 0.000 claims 2
• 229960005475 antiinfective agent Drugs 0.000 claims 2
• 239000003524 antilipemic agent Substances 0.000 claims 2
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
• 229960004666 glucagon Drugs 0.000 claims 2
• 229940125396 insulin Drugs 0.000 claims 2
• 230000000291 postprandial effect Effects 0.000 claims 2
• 230000001737 promoting effect Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 102000008186 Collagen Human genes 0.000 claims 1
• 108010035532 Collagen Proteins 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
• 206010061218 Inflammation Diseases 0.000 claims 1
• 229940127003 anti-diabetic drug Drugs 0.000 claims 1
• 230000002924 anti-infective effect Effects 0.000 claims 1
• 229940125708 antidiabetic agent Drugs 0.000 claims 1
• 229940030600 antihypertensive agent Drugs 0.000 claims 1
• 229940127088 antihypertensive drug Drugs 0.000 claims 1
• 239000004599 antimicrobial Substances 0.000 claims 1
• 229960004676 antithrombotic agent Drugs 0.000 claims 1
• 229940127217 antithrombotic drug Drugs 0.000 claims 1
• -1 antithrombotic drugs Substances 0.000 claims 1
• 230000006907 apoptotic process Effects 0.000 claims 1
• 239000002327 cardiovascular agent Substances 0.000 claims 1
• 229940125692 cardiovascular agent Drugs 0.000 claims 1
• 208000026106 cerebrovascular disease Diseases 0.000 claims 1
• 229920001436 collagen Polymers 0.000 claims 1
• 230000008021 deposition Effects 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 claims 1
• 108091005995 glycated hemoglobin Proteins 0.000 claims 1
• 230000004054 inflammatory process Effects 0.000 claims 1
• 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
• 108010049112 miniplasminogen Proteins 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 230000000638 stimulation Effects 0.000 claims 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1